In an interview with Pharm Exec associate editor Don Tracy, Pedro Valencia, vice president of solid tumor pipeline strategy and execution at AbbVie, discusses the ABBV-400 and ABBV-706 data from multiple studies presented at ASCO.
AbbVie Presents New Data for Two Antibody-Drug Conjugates in Multiple Indications at ASCO 2024
Leave a comment
